Alectinib rescue therapy in advanced ALK rearranged lung adenocarcinoma: a case report

被引：0
|
作者：
Cesaro, Cristiano [1 ,7 ]
Caterino, Umberto [1 ]
Perrotta, Fabio [2 ]
Masi, Umberto [2 ]
Cotroneo, Alessandra [2 ]
Cianci, Roberta [2 ]
Zamparelli, Enzo [3 ]
Cesaro, Flavio [4 ]
Amore, Dario [5 ]
Rocco, Danilo [6 ]
机构：
[1] Azienda Osped Colli, Monaldi Hosp, Unit Bronchol, Naples, Italy
[2] Univ Campania L Vanvitelli, Azienda Osped Colli, Monaldi Hosp, Unit Pulmonol, Naples, Italy
[3] Azienda Osped Colli, Monaldi Hosp, Unit Anesthesia & Resuscitat, Naples, Italy
[4] CTO Hosp, Unit Emergency Med & Surg & Aid 1, Naples, Italy
[5] Azienda Osped Colli, Monaldi Hosp, Unit Thorac Surg, Naples, Italy
[6] Azienda Osped Colli, Monaldi Hosp, Unit Oncol Pulmonol, Naples, Italy
[7] AO Colli Naples, Monaldi Hosp, Unit Bronchol, Via Leonardo Bianchi, I-80131 Naples, Italy
来源：
MONALDI ARCHIVES FOR CHEST DISEASE | 2023年 / 93卷 / 03期
关键词：
lung adenocarcinoma; malignant pleural effusion; anaplas-tic lymphoma kinase inhibitor therapy (ALK); CANCER;
D O I：
10.4081/monaldi.2022.2388
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) that is approved as first-line treatment in adult patients with ALK-positive non-small cell lung cancer (NSCLC) and as second-line in patients previously treated with crizotinib, and has been shown in the literature to significantly prolong progression-free survival compared to chemotherapy in patients with advanced non-small cell lung cancer. The authors describe a clinical case of a 24-year-old woman with malignant massive pleural effusion caused by ALK rearranged pulmonary adenocarcinoma with pleural and pericardial metastasis, in which, despite a dramatic clinical debut, the correct and timely management of the diagnostic and therapeutic path allowed for extraordinary therapeutic success.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy
    Cao, Peijun
    Zhao, Qingchun
    Li, Yongwen
    Shi, Ruifeng
    Zhu, Guangsheng
    Zhang, Zihe
    Zhang, Hongbing
    Liu, Minghui
    Wei, Sen
    Liu, Hongyu
    Chen, Jun
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [2] Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
    Imanishi, Naoko
    Yoneda, Kazue
    Taira, Akihiro
    Ichiki, Yoshinobu
    Sato, Naoko
    Hisaoka, Masanori
    Tanaka, Fumihiro
    [J]. SURGICAL CASE REPORTS, 2018, 4
  • [3] Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
    Naoko Imanishi
    Kazue Yoneda
    Akihiro Taira
    Yoshinobu Ichiki
    Naoko Sato
    Masanori Hisaoka
    Fumihiro Tanaka
    [J]. Surgical Case Reports, 4 (1)
  • [4] SCLC Transformation from ALK-rearranged Lung Adenocarcinoma after Alectinib Resistance and Response to Atezolizumab: Case Report
    Xia, G.
    Yu, S.
    Ni, J.
    Song, M.
    Zhang, J.
    Huang, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S526 - S527
  • [5] Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report
    Tang, Quanying
    Li, Tong
    Ren, Fan
    Li, Xuanguang
    Cao, WeiBo
    Yu, Haochuan
    Mao, Fuling
    Cao, Cancan
    Zu, Lingling
    Xu, Song
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (02):
  • [6] First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report
    Scarfone, Giovanna
    Fumagalli, Monica
    Imbimbo, Martina
    Ceruti, Tommaso
    Cribiu, Fulvia Milena
    Di Loreto, Eugenia
    D'Incalci, Maurizio
    Facchin, Federica
    Fontana, Camilla
    Garassino, Marina C.
    Peccatori, Fedro A.
    Persico, Nicola
    Signorelli, Diego
    Zucchetti, Massimo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (05) : 873 - 877
  • [7] ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report
    Gonzalez-Mosquera, Luis F.
    Abu Rous, Fawzi
    Rogers, Alexandra
    Smith, Nicolina
    Goyert, Gregory
    Gadgeel, Shirish
    [J]. CLINICAL LUNG CANCER, 2024, 25 (02) : e77 - e80
  • [8] High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report
    Li, Yan
    Duan, Peng
    Guan, Yan
    Chen, Qing
    Grenda, Anna
    Christopoulos, Petros
    Denis, Marc G.
    Guo, Qisen
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (01) : 100 - 110
  • [9] Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
    Rao, Chuangzhou
    Nie, Liangqin
    Wu, Xiaokang
    Miao, Xiaobo
    Chen, Ting
    Chen, Liuxi
    Zhang, Dongqing
    Lin, Quan
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
    Nobuaki Mamesaya
    Kazuhisa Nakashima
    Tateaki Naito
    Takashi Nakajima
    Masahiro Endo
    Toshiaki Takahashi
    [J]. BMC Cancer, 17
12345